利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

59 条记录 (耗时 0.013 秒)

    DIAGNOSIS OF AUTISM SPECTRUM DISORDER BY MULTIOMICS PLATFORM
    24.
    发明申请
    DIAGNOSIS OF AUTISM SPECTRUM DISORDER BY MULTIOMICS PLATFORM 审中-公开

    公开(公告)号：WO2022249182A2

    公开(公告)日：2022-12-01

    申请号：PCT/IL2022/050555

    申请日：2022-05-25

    申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.

    发明人： AMAL, Haitham

    IPC分类号： G01N33/68 ,  G01N33/497 ,  G16H50/70 ,  G01N2440/14 ,  G01N2440/26 ,  G01N33/6896 ,  G16B25/10 ,  G16H50/20

    摘要： The present invention is directed to methods for determining an autism spectrum condition in a subject. The methods comprise determining in a sample obtained from the subject any one of: (i) an elevated expression level of at least one biomarker selected from Table 2; (ii) a reduced expression level of at least one biomarker selected from Table 3; (iii) phosphorylation of at least one biomarker selected from Table 4; (iv) S-nitrosylation (SNO) of at least one biomarker selected from Table 5; (v) a volatile organic compound (VOC) profile comprising at least one VOC selected from any one of Table la, Table lb, Table lc, Table Id, Table le, (vi) any combination of (i) to (v), wherein a significant change of the at least one biomarker in said sample compared to control, is indicative of the subject being afflicted with an autism spectrum condition. Further provided is a kit suitable for determining an autism spectrum condition.

    METHODS OF EVALUATING BRAIN INJURY IN A PEDIATRIC SUBJECT
    25.
    发明申请
    METHODS OF EVALUATING BRAIN INJURY IN A PEDIATRIC SUBJECT 审中-公开

    公开(公告)号：WO2022245920A1

    公开(公告)日：2022-11-24

    申请号：PCT/US2022/029798

    申请日：2022-05-18

    申请人： ABBOTT LABORATORIES

    发明人： MCQUISTON, Beth ,  DATWYLER, Saul ,  CHANDRAN, Raj ,  ZHANG, Hongwei ,  MARINO, Jaime

    IPC分类号： G01N33/68 ,  G01N2800/28 ,  G01N33/6896

    摘要： Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a pediatric subject for traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a pediatric subject would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP, UCH-L1 or GFAP and UCH-L1.

    DIAGNOSIS OF ALZHEIMER'S DISEASE BY DETECTING AUTO-ANTIBODIES AGAINST Y-BOX BINDING PROTEIN-1 (YB-1)
    27.
    发明申请
    DIAGNOSIS OF ALZHEIMER'S DISEASE BY DETECTING AUTO-ANTIBODIES AGAINST Y-BOX BINDING PROTEIN-1 (YB-1) 审中-公开

    公开(公告)号：WO2022200355A1

    公开(公告)日：2022-09-29

    申请号：PCT/EP2022/057501

    申请日：2022-03-22

    申请人： CELLTREND GMBH

    IPC分类号： G01N33/68 ,  G01N33/6896

    摘要： The present invention relates to a method for the diagnosis of Alzheimer's Disease, comprising the steps of (i) determining the level of antibodies against YB-1 in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without Alzheimer's Disease, wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative of Alzheimer's Disease in the subject.

    BIOLOGICAL VESICLES ISOLATION AND DISCOVERY METHODS AND SYSTEMS
    28.
    发明申请
    BIOLOGICAL VESICLES ISOLATION AND DISCOVERY METHODS AND SYSTEMS 审中-公开

    公开(公告)号：WO2021260231A1

    公开(公告)日：2021-12-30

    申请号：PCT/EP2021/067748

    申请日：2021-06-28

    申请人： MURSLA LIMITED

    发明人： DIAS, Tomás Miguel De Freitas ,  ARSÈNE, Pierre

    IPC分类号： G01N1/28 ,  G01N33/543 ,  G01N33/68 ,  C12N7/02 ,  C12Q1/68 ,  C12Q1/70 ,  C12Q1/6806 ,  C12N7/00 ,  C12Q1/6883 ,  G01N2333/70596 ,  G01N33/5076 ,  G01N33/54326 ,  G01N33/54346 ,  G01N33/54353 ,  G01N33/6896

    摘要： A method of isolating target extracellular vesicles, EVs or target viruses from a biofluid comprising a plurality of target EVs and target viruses and non-target EVs and non-target viruses, comprising: introducing a plurality of EV or viral capture microparticles to the biofluid to obtain a precursor mixture, wherein the plurality of EV or viral capture microparticles are functionalised, via a plurality of first linkers, with EV or viral-specific binding agents specific to an EV or first viral surface marker, such that a plurality of bound microparticle-EV and bound viral-microparticle assemblies is formed in the precursor mixture; extracting the bound microparticle-EV/microparticle-viral assemblies; introducing a plurality of target or viral capture nanoparticles, wherein the plurality of target or viral capture nanoparticles are functionalised with target or viral-specific binding agents receptive to surface markers comprised on the target EVs or a second viral surface marker, such that the target or viral capture nanoparticles bind to the plurality of target EVs or target viruses; cleaving the plurality of first linkers to dissociate at least the plurality of target EVs or target viruses from the EV or viral capture microparticles; after the cleaving, extracting the plurality of EV or viral capture microparticles and applying at least one of dielectrophoresis or centrifugation to extract the plurality of target or viral capture nanoparticles, such that the target EVs or viruses are separated from the non-target EVs or non-target viruses.